Form 4: Kairos Pharma CEO John S Yu Reports Acquisition of 14,000 Restricted Stock Units

John S Yu, CEO and Chairman of Kairos Pharma, reports the acquisition of 14,000 restricted stock units (RSUs) and provides an update on his beneficial ownership of the company's common stock.

Summary

• On January 1, 2025, John S Yu, CEO and Chairman of Kairos Pharma, acquired 14,000 restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.
• These RSUs vest in three increments: one-third on January 1, 2025, one-third on September 16, 2025, and one-third on September 16, 2026.
• As of the reporting date, 4,667 RSUs have vested.
• Following the reported transaction, Yu's beneficial ownership consists of 5,346,504 shares of common stock and 9,334 unvested RSUs.
• The acquisition was reported on February 24, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The grant of RSUs to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, reporting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Key Dates

Keywords

Kairos Pharma, John S Yu, restricted stock units, RSUs, beneficial ownership, Form 4, Equity Incentive Plan, CEO, Chairman